About the Study
Research Center: Imaging Endpoints
Location: 9977 N. 95th street, Suite 101 Scottsdale, AZ 85258
Lead Doctor: Dr. Allan M. Block
IRB Committee: This study has been reviewed and approved by WIRB-Copernicus Institutional Review Board
Living with Parkinson’s disease can be a struggle. To add to the physical challenges of the disease, problems with thinking and memory can also arise. These thinking and memory problems are called mild cognitive impairment. It can affect 15% to 25% of newly diagnosed Parkinson’s patients.
This study seeks to evaluate the effectiveness of an investigational medication that may help people with mild cognitive impairment linked with Parkinson’s disease.
- Participants may experience improvements to their thinking and memory problems.
- Participants may be able to manage symptoms of mild cognitive impairment.
- Participants will be compensated for their time and travel.
- Participants will be helping to advance medical research on Parkinson’s Disease.
- If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.
- Your records relating to this study and any other information received will be kept strictly confidential, except as required by the law.
- Qualified health professionals will monitor your health as it relates to the study.
Who Can Participate?
- Must be diagnosed with Parkinson’s disease.
- Must be aged 50 to 85 years old.
- Must be diagnosed with mild cognitive impairment associated with Parkinson’s disease (have symptoms such as having a hard time paying attention, difficulties with problem-solving, slowed thinking and issues with short-term memory), have mild dementia or have been diagnosed with mild dementia.
- Must have a study partner to assist them during the study.
- A study partner is someone who has frequent contact with the study participant and is willing and able to provide information about the participant and attend some study visits.
- Able to attend 7 study visits at the research site over approximately 14 weeks as well as answer 3 study-related phone calls.